|
|
|
Posted 11 April 2024 AM
AstraZeneca, Novartis and MSD have been the biggest PBAC players over the past four years, each making more than 30 submissions, exclusive Pharma in Focus analysis shows.
The analysis looked at all submissions made by pharmas from 1 January 2020 to 31 December 2023 and includes those considered 'not applicable', meaning they were either withdrawn or considered at a future meeting.
AstraZeneca took the number one position with a massive total of 49 submissions, covering 17 medicines.
It made the most submissions for its PARP inhibitor Lynparza - 10 in total - followed by SGLT2 inhibitor Forixga and BTK inhibitor Calquence, which each had eight submissions.
Sitting behind AstraZeneca in second place with a total of 36 submissions is Novartis, covering 15 medicines.
 |
Cosentyx, a monoclonal antibody used for a range of inflammatory conditions, appeared the most with six submissions, followed by the company's gene therapy for spinal muscular atrophy Zolgenmsa at five.
Novartis' siRNA therapy Leqvio, JAK inhibitor Jakavi, and VEGF inhibitor Beovu were also each submitted three times over the reporting period.
Meanwhile, MSD had a total of 31 submissions, although the majority were seeking to expand its PD-1 inhibitor Keytruda, currently one of the world's top-selling drugs.
Keytruda appeared in 23 submissions while the remaining submissions covered Covid antiviral Lagevrio, antiparasitic Stromectol, monoclonal antibody Zinplava and two biosimilars - Brenzys and Hadlima.
Tied in fourth and fifth place was BMS and AbbVie, each with 29 submissions.
BMS' PD-1 inhibitor Opdivo appeared in 19 submissions (sometimes in combination with Yervoy) while AbbVie's JAK inhibitor Rinvoq appeared in 13 submissions followed by monoclonal antibody Skyrizi at six.
Tied in sixth and seventh spot was Pfizer and Janssen, each with 27 submissions.
Pfizer's submissions covered 17 medicines while Janssen's covered 11 with hormone therapy Erlyand and monoclonal antibody Stelara appearing the most.
Sanofi snagged eighth spot with 21 submissions, of which eight cover monoclonal antibody Dupixent and six cover PD-1 inhibitor Libtayo but was closely followed by Bayer with 20 submissions.
Bayer's submissions covered seven medicines, although half of the total submissions covered hormone therapy Nubeqa and TRK inhibitor Vitrakvi.
Rounding up the Top 10 list is Amgen with a total of 18 submissions, which cover seven drugs, including five submissions for PDE4 inhibitor Otezla.
 |
Tiffany Walker
If you were passed this article by a colleague, chances are you've missed other important Pharma in Focus articles and features.
To find out more, go to www.pharmainfocus.com.au and sign up for a FREE Full Text trial
Pharma in Focus
Australia's most trusted source of pharma news
© Copyright Lush Media. End of News - printed 04 December 2024